Group 1 - The Shanghai Composite Index fell by 0.02% to close at 3727.29 points, while the Hang Seng Index decreased by 0.21% to 25122.9 points [1] - Fudan Zhangjiang's A/H premium reached 183.21%, ranking third among A/H shares [1] - At market close, Fudan Zhangjiang's A-shares were priced at 10.48 yuan, down 1.87%, and H-shares were at 4.02 HKD, down 1.95% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and "Major New Drug Creation" projects [1]

Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - Fudan Zhangjiang's A/H premium reached 183.79%, ranking third among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.68 yuan, with a gain of 2.01%, and H-shares closed at 4.1 Hong Kong dollars, up by 2.24% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovative enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology, with new drugs expected to be launched in the market [1]

8月12日，上证指数涨0.5%，收报3665.92点，恒生指数涨0.25%，收报24969.68点。 本文源自：金融界 作者：行情君 资料显示，上海复旦张江生物医药股份有限公司,一九九六年十一月创建于上海浦东张江高科技园区,由 知名企业如上海医药集团股份有限公司等作为公司股东。本着"我们多一分探索、人类多一分健康"的信 念,公司主要从事生物医药的创新研究、开发、生产和销售,力求成为一家以知识产权为核心源泉的生物 医药创新企业。经过多年的不懈努力,公司在基因技术药物、光动力技术药物、纳米技术药物及口服固 体制剂技术药物等领域不断推出新技术及产品,形成了明显的竞争优势,预计未来将陆续有新药投放市 场。凭籍在生物医药领域的实力,公司多次承担"国家重点科技项目(攻关)计划"、"国家高技术研究发展 计划(八六三计划)"、"'重大新药创制'科技重大专项"等。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 复旦张江AH溢价达187.84%，位居AH股溢价率第三位。当日收盘，复旦张江A股报10.52元，跌幅 2.05%，H股报3.99港元，下跌2.68%。 ...

Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - Fudan Zhangjiang's A/H premium reached 177.33%, ranking fourth among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.92 yuan, down 0.27%, and H-shares closed at 4.3 HKD, up 1.65% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic technology drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Composite Index and the Hang Seng Index, with the former declining by 0.37% to close at 3559.95 points and the latter dropping by 1.07% to 24507.81 points [1] - Fudan Zhangjiang's A/H share premium reached 182.7%, ranking fourth among A/H shares, with A-shares closing at 10.83 yuan (up 0.19%) and H-shares at 4.17 HKD (up 1.96%) [1] - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] Group 2 - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and "Major New Drug Creation" projects [1]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on July 29, with the former rising by 0.33% to close at 3609.71 points and the latter falling by 0.15% to close at 25524.45 points [1] - Fudan Zhangjiang's A/H share premium reached 171.57%, ranking fourth among A/H shares, with A shares closing at 10.75 yuan (up 2.97%) and H shares at 4.33 HKD (up 2.61%) [1] - Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] Group 2 - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Over the years, the company has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and the "Major New Drug Creation" science and technology major special project [1]